Efficacy of imeglimin in patients with type 2 diabetes mellitus complicated by metabolic dysfunction‐associated steatotic liver disease: A multicentre study
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16157 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Kensaku Fukunaga und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Faculty of Medicine, Kagawa University, Miki-cho, Kagawa, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Liver Cirrhosis, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
This study aimed to evaluate the effectiveness of imeglimin in improving liver function and fibrosis in patients with type 2 diabetes (T2D) complicated by metabolic dysfunction‐associated steatotic liver disease (MASLD). Materials and Methods We conducted a multicentre study involving 80 patients with T2D and MASLD who were treated with or without imeglimin for 24 weeks. We assessed the changes in diabetes‐related parameters, including HbA1c, fasting blood glucose, glycoalbumin and C‐peptide index. Liver function was monitored using AST, ALT, γ‐GTP and liver fibrosis indicators such as Fib‐4 index and FibroScan‐AST (FAST) score. Liver fat content and stiffness were measured using controlled attenuation parameter and vibration‐controlled transient elastography, which were measured using FibroScan.
Results
Compared with the control group, imeglimin treatment led to a significant reduction in HbA1c levels, fasting blood glucose and liver‐related parameters, including AST, ALT and γ‐GTP. Additionally, the Fib‐4 index and FAST score, which reflect liver fibrosis and inflammation, were significantly lower in the imeglimin group. Liver fat content and stiffness remained unchanged during the study period.
Conclusions
Imeglimin efficaciously improved liver inflammation and fibrosis in patients with T2D and MASLD, with no significant changes in liver fat content or stiffness. These findings suggest that imeglimin is a promising therapeutic drug for the management of MASLD in the context of T2D, warranting further research on its long‐term efficacy and mechanisms of action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Faculty of Medicine, Kagawa University, Miki-cho, Kagawa, Japan.
- Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki-cho, Kagawa, Japan.
ORCID-Profile: Kensaku Fukunaga
Zitieren
APA
Fukunaga, K., Morishita, A., Imachi, H., Oura, K., Sato, S., Kobayashi, T., Saheki, T., Yoshimura, T., Komori, K., Nakahara, M., Tadokoro, T., Fujita, K., Tani, J., Kobara, H., & Murao, K. (2025). Efficacy of imeglimin in patients with type 2 diabetes mellitus complicated by metabolic dysfunction‐associated steatotic liver disease: A multicentre study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16157
Vancouver
Fukunaga K, Morishita A, Imachi H, Oura K, Sato S, Kobayashi T, et al. Efficacy of imeglimin in patients with type 2 diabetes mellitus complicated by metabolic dysfunction‐associated steatotic liver disease: A multicentre study. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16157
BibTeX
@article{Fukunaga2025,
author = {Fukunaga, Kensaku and Morishita, Asahiro and Imachi, Hitomi and Oura, Kyoko and Sato, Seisuke and Kobayashi, Toshihiro and Saheki, Takanobu and Yoshimura, Takafumi and Komori, Kurumi and Nakahara, Mai and Tadokoro, Tomoko and Fujita, Koji and Tani, Joji and Kobara, Hideki and Murao, Koji},
title = {Efficacy of imeglimin in patients with type 2 diabetes mellitus complicated by metabolic dysfunction‐associated steatotic liver disease: A multicentre study},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16157}
}
EUVIMED